FY4/21
Supplementary Materials

June 4, 2021

１．Consolidated Results■Year-on-Year
FY4/20results

FY4/21
results

YoYchange(¥ million)
YoYchange(%)

Net sales

292,615

297,305+4,690+1.6

Gross profit

46,861

46,155(706)(1.5)

30,79335,222+4,429+14.4

16,068

10,932(5,136)(32.0)

16,822

12,649(4,173)(24.8)

Profit attributableto owners of parent

9,179

6,697(2,482)(27.0)

Earnings pershare(¥)

259.11189.04(70.08)(27.0)% of net sales

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales

16.0

15.5

10.5

11.8

5.5

3.7

5.7

4.3

3.1

% of net sales

2.3

Figures in the table are rounded down

■Vs Plan
FY4/21
revised plan

FY4/21
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

300,000

297,305(2,695)(0.9)

Gross profit

45,40046,155+755+1.7

36,20035,222

(978)

(2.7)

9,200

10,932+1,732+18.8

10,00012,649+2,649+26.5

Profit attributableto owners of parent

5,000

6,697+1,697+33.9

Earnings pershare(¥)

141.13189.04

+47.9

+33.9

% of net sales

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales

15.1

15.5

12.1

11.8

3.1

3.7

3.3

4.3

1.7

% of net sales

Figures in the table are rounded down

2.3

-1-

２. Segment Information(Dispensing Pharmacy Business)■Year-on-Year
FY4/20results

FY4/21
results

YoYchange(¥ million)
YoYchange(%)

Net sales

263,750

263,095(655)(0.2)

Gross profit

34,96033,160(1,800)(5.1)

SG&A expenses

14,664

13,998(666)(4.5)

Operating income

20,295

19,162

7.7

7.3(1,133)(5.6)

Segment income

20,85020,947+97+0.5% of net sales% of net sales% of net sales% of net sales

13.3

12.6

5.6

5.3

7.9

8.0

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the consolidated statements of income■Vs Plan

FY4/21
revised plan

FY4/21
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

264,800

263,095(1,705)(0.6)

Gross profit

32,40033,160+760+2.3

SG&A expenses14,900

13,998(902)(6.1)

Operating income

17,50019,162

6.6

7.3+1,662+9.5

Segment income

18,20020,947+2,747+15.1% of net sales% of net sales% of net sales% of net sales

12.2

12.6

5.6

5.3

6.9

8.0

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the consolidated statements of income-2-3. Segment Information(Cosmetic and Drug Store Business)■Year-on-Year
FY4/20results

FY4/21
results

YoYchange(¥ million)
YoYchange(%)

Net sales

24,701

19,419(5,282)(21.4)

Gross profit

9,753

7,216(2,537)(26.0)

39.5

37.2

SG&A expenses

9,596

9,358(238)(2.5)

Operating income

157(2,141)(2,298)-Segment income

262(1,999)(2,261)-% of net sales% of net sales% of net sales% of net sales

38.8

48.2

0.6

-

1.1

-

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the consolidated statements of income■Vs Plan
FY4/21
revised plan

FY4/21
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

20,00019,419(581)(2.9)

Gross profit

7,3307,216(114)(1.6)

SG&A expenses

9,680

9,358(322)(3.3)

Operating income(2,350)(2,141)+209-

Segment income(2,200)(1,999)+201-% of net sales% of net sales% of net sales% of net sales

36.7

37.2

48.4

48.2

----

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the consolidated statements of income-3-4. Sales Verification(%) ■Dispensing Pharmacy Business(Vs Plan) (%)
Average
Average
Prescription
Prescription
Net salesprescription
prescription
volumevolumepriceprice■Dispensing Pharmacy Business (YoY)
Net sales
Same store (1,020)

(2.8)

(9.1)

+7.0

Same store (1,020)

+0.5

(3.2)

+3.8

Store openings in theprevious year (16)+354.4+269.7+23.0

Store openings in theprevious year (16)

(4.2)

(4.3)

(0.5)

(0.2)

(8.6)

+9.3

Total (1,065)

(0.5)

(2.5)

+2.1

Total (1,065)■Cosmetic and Drug Store Business(YoY)
Net sales(%) ■Cosmetic and Drug Store Business (Vs Plan) (%)

Average
Number ofspending percustomers
customer

Net sales

Average
Number ofspending percustomers
customerSame store (42)(25.6)(22.9)(3.5)

Same store (42)+0.3+4.3(3.8)

Store openings in theprevious year (15)

+70.2

+71.1

(0.5)

Store openings in theprevious year (15)

(8.7)

(5.3)

(3.5)

Total (69)(21.6)(19.5)(2.6)

Total (69)

(2.9)

+0.6

(3.5)

-4-5. Consolidated Balance Sheet■Assets
Cash on hand and in banks
Notes and accounts receivable
Inventories
Total current assets
Buildings and structures,net
Land
Lease assets
Total property,plant andequipment
Goodwill
Lease assets
Total intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total fixed assets
Total deferred assets
Total assets(¥ million)
End-FY4/19

End-FY4/20

End-FY4/21

Change48,091
12,771
12,89885,446
16,352
10,394571

46,321
13,653
15,32287,802
16,60910,960272

55,271
13,475
14,28596,398
16,270
10,390100+8,950(178)(1,037)+8,596
(339)
(570)
(172)

30,18630,87430,229(645)

45,2497
47,577
1,795
4,284
15,13342,123
5
44,916
2,295
4,211
19,14439,057
1
42,666
2,697
4,415
20,319(3,066)(4)(2,250)+402+204+1,17525,751

29,84134,368+4,527

103,51559
189,021

105,632
15
193,451

107,264
203,662+1,632(15)+10,211

Figures in the table are rounded down

Change:End-FY4/21 compared with end-FY4/20
Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥8,122 million(¥ million)■Liabilities and Net Assets

End-FY4/19

End-FY4/20

End-FY4/21

Total liabilities and net assets

44,794
5,571
318
73,744
5,985
401
11,35585,09921,89420,50061,526
103,920
103,922
189,021

Figures in the table are rounded down

Change:End-FY4/21 compared with end-FY4/20

Accounts payable
Short-term debt
Lease obligations
Total current liabilities
Long-term debt
Lease obligations
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

47,1873,642193
74,700
2,432
154
7,747
82,447
21,89420,50068,758111,151
111,003
193,451-5-

46,7583,670
94
74,1608,297
3713,66487,82521,89420,50073,506
115,899
115,837
203,662

Change(429)+28(99)(540)+5,865(117)+5,917+5,378+4,748+4,748+4,834+10,211

6. FY4/22 Plan (Consolidated)

FY4/20results

FY4/21
results

YoYchangeFY4/22plan(¥ million)
YoYchange (%)

Net sales

292,615

297,305

315,000+17,695+6.0

Gross profit

46,861

46,15551,600+5,445+11.830,793

35,22236,600+1,378+3.9

16,068

10,932

15,000+4,068+37.2

16,822

12,64915,500+2,851+22.5

Profit attributableto owners of parent

9,179

6,697

8,300

+1,603+23.9

Earnings pershare(¥)

259.11189.04234.28+45.24+23.9

Annual dividend (¥)

55.00

55.00

55.00

0.0

0.0

% of net sales

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales% of net sales

16.0

10.5

5.5

5.7

3.1

15.5

11.8

3.7

4.3

2.3

Figures in the table are rounded downChange:FY4/22 plan compared with FY4/21 results-6-16.4

11.64.84.92.6

7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/13 FY4/14 FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21Organic

383640322725231415

M&A382611911018211134

614Total

560616754881

1,066

1,029

1,132

1,0881,065■Number of Store Openings in Cosmetic and Drug Store Business
FY4/13 FY4/14 FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21Organic73359471511Total

615956525248

546369Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-